New drug combo shows promise in shrinking breast tumors before surgery

NCT ID NCT07396324

Recruiting now Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Feb 10, 2026 · Last updated May 21, 2026 · Updated 15 times

Summary

This study tests a new drug called QL1706 (a mix of two immune-boosting medicines) combined with standard chemotherapy given before surgery for people with a common type of breast cancer (HR-positive, HER2-negative). The goal is to see if this combination can eliminate all cancer cells in the breast tissue at the time of surgery. About 55 adults with early-stage, non-metastatic breast cancer will take part. The study is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITING

Shanghai, 200127, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HORMONE RECEPTOR POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER HR-POSITIVE/HER2-NEGATIVE BREAST CANCER